Concepedia

Darren C. Phillips

DC

Statistics

Publications

34

Citations

6.4K

H-Index

26

Active since

2002

Affiliations

AbbVie (United States)(Current)

St. Jude Children's Research Hospital

Aston University

The University of Melbourne

Walter and Eliza Hall Institute of Medical Research

Darren C. Phillips is an author at AbbVie (United States) specializing in oncology, pharmacology, and molecular oncology.

Publications per year

2002–2025

34

Publications

34

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

H Zhang, J Chen, Sajid Khan Tahir et al. · Cell Death and Disease · 2015 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 331 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis

Sha Jin, Dan Cojocari, Julie J. Purkal et al. · Clinical Cancer Research · 2020 · 194 citations

Medicine, Oncology, Pharmacology +16

1–5 of 34